Nadja Jaekel

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

Haifa Kathrin Al‐Ali, Nadja Jaekel, Georg Maschmeyer et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 114 citations

Hematological Malignancy, Oncology, Health Sciences +12

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

Nadja Jaekel, Gerhard Behre, A Behning et al. · Bone Marrow Transplantation · 2013 · 107 citations

Hematological Malignancy, Jak2 Inhibitor Ruxolitinib, Transplantation +8

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

Dieter Hoelzer, Andreas Huettmann, Felix Kaul et al. · Blood · 2010 · 83 citations

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Raphaël Itzykson, Valeria Santini, Sylvain Thépot et al. · Journal of Clinical Oncology · 2022 · 40 citations · Full text

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

Nadja Jaekel, K Lieder, Stefan Albrecht et al. · Bone Marrow Transplantation · 2015 · 34 citations

Non-thalassemic Patients, Transplantation, Marrow Transplantation +8